Default Category
-
DSD Dillinger Stahlbau GmbH (A)
Gallo, Miguel Ángel; Slof E. J.Case DG-944-EStrategyStarting at €8.20
-
DSD Dillinger Stahlbau GmbH (B)
Gallo, Miguel Ángel; Slof E. J.Case DG-945-EStrategyStarting at €5.74
-
-
DSD Dillinger Stahlbau GmbH (B)
Gallo, Miguel Ángel; Slof E. J.Case DG-945StrategyThe case deals with the troubles a sizable West German steel construction company encounters changing from the generation of managers who governed the company since its foundation and who grew into their jobs to a generation of professional managers. This transition is further complicated by the fact that the families who own the majority of the company's shares, would like to continue family participation in the management. These problems are th...Starting at €5.74
-
GSK’s Andrew Witty: Addressing Neglected Tropical Diseases and Global Health Issues — Open Labs, Open Minds (B)
Michael J. Rouse; Chander SehgalCase IVEY-9B10M110-EStrategyThis case is a supplement to GSK’s Andrew Witty (A).Starting at €5.74
-
DSD Dillinger Stahlbau GmbH (A)
Gallo, Miguel Ángel; Slof E. J.Case DG-944StrategyThe case describes the foundation of a West German steel construction company shortly after World War II and its amazingly succesful growth during the 1950's, 1960's and 1970's. It deals specifically with the major acquisitions, takeovers and new establishments the company undertook during the period under concern, as well as with its approach to internationalization and financial growth. The company's high level of expansion is contrasted with a...Starting at €8.20
-
GSK’s Andrew Witty: Addressing Neglected Tropical Diseases and Global Health Issues — The Pharmaceutical Patent Pool (A)
Michael J. Rouse; Chander SehgalCase IVEY-9B10M109-EStrategyIn February 2009, Andrew Witty, CEO of GlaxoSmithKline (GSK), reflected on his vision for big pharma as a catalyst for change which focussed on two key issues: 1) promoting innovation for the products that treat or prevent neglected tropical diseases and 2) improving access to medicines in the world’s poorest countries. He had announced the creation of the Pharmaceutical Patent Pool and wondered if it was the right strategy to deliver results on ...Starting at €8.20